

DISCUSSION OF THE AMENDMENT

Claims 1, 2 and 5 have each been amended by changing "capable of forming" to -- that forms-- with regard to X¹, and by deleting "capable of bonding the two ligands to each other" with regard to A¹ and A². Claims 11 and 12 have been canceled.

No new matter is believed to have been added by the above amendment. With entry thereof, Claims 1-7, 9, and 13 will be pending in the application.

REMARKS

The rejection of Claims 11 and 12 under 35 U.S.C. § 103(a) as unpatentable over various prior art is now moot in view of the cancellation of these claims. Accordingly, it is respectfully requested that the rejections be withdrawn.

The objections to Claims 1, 2 and 5 are respectfully traversed. Indeed, the objections are now moot in view of the above-discussed amendment. Accordingly, it is respectfully requested that the objections be withdrawn.

All of the presently-pending claims in this application are now believed to be in immediate condition for allowance. Accordingly, the Examiner is respectfully requested to pass this application to issue.

Respectfully submitted,


Customer Number

22850

Tel: (703) 413-3000
Fax: (703) 413 -2220
(OSMMN 03/06)

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.

Norman F. Oblon



Harris A. Pitlick
Registration No. 38,779

NFO:HAP: